In August 2023, the Food and Drug Administration issued two draft guidance, both related to the development of biosimilar products, entitled “Formal Meetings between the FDA and Sponsors or Applicants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback